The results of the CANVAS Program, in which Stanford Department of Medicine faculty played several leading roles, were presented on June 12, 2017, during the 77^th annual meeting of the American Diabetes Association in San Diego.

The CANVAS Program (CANagliflozin CardioVascular Assessment Study) investigated canagliflozin, a drug for patients with type 2 diabetes who were at high risk of cardiovascular events, in over 10,000 participants who were followed over an average of three years.  The study showed that canagliflozin significantly reduced cardiovascular death, nonfatal myocardial infarction or nonfatal stroke by 14% compared with placebo. Canagiflozin increased the risk of amputation – usually at the level of toe or metatarsal.

Stanford DOM participants in the CANVAS Program included Kenneth Mahaffey, MD, a member of the Steering Committee; Mark Hlatky, MD, and Nicholas Leeper, MD, members of the Cardiovascular Adjudication Committee; and Tara Chang, MD, MS, a member of the Renal Adjudication Committee.  The adjudication work was coordinated through the Stanford Center for Clinical Research (SCCR).

The trial manuscript was published in The New England Journal of Medicine simultaneously with the presentation of the results: http://www.nejm.org/doi/full/10.1056/NEJMoa1611925